Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$70.13
+0.2%
$23.93
$4.77
$75.51
$4.44B0.563.24 million shs667,272 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$4.53
+1.8%
$4.17
$1.45
$12.76
$147.73M1.36407,692 shs190,632 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.55
+0.7%
$3.98
$2.28
$6.71
$573.38M1.76846,873 shs1.39 million shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$8.05
$7.99
$1.31
$8.10
$383.91M3.331.09 million shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+0.16%-2.52%+743.92%+945.16%+522.82%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+1.80%-1.74%-1.52%+68.40%-61.35%
Organogenesis stock logo
ORGO
Organogenesis
+0.66%+0.89%+2.02%+49.18%+82.00%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
0.00%0.00%+0.50%+232.64%+148.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3.4715 of 5 stars
4.64.00.00.02.20.80.6
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.3279 of 5 stars
3.51.00.00.02.42.50.6
Organogenesis stock logo
ORGO
Organogenesis
4.2983 of 5 stars
3.32.00.04.32.44.20.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.0979 of 5 stars
4.03.00.00.01.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3.13
Buy$92.3331.66% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
3.00
Buy$17.17278.96% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5064.84% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8034.16% Upside

Current Analyst Ratings Breakdown

Latest LXEO, VIGL, ORGO, and ABVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/31/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$20.00
7/29/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$74.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$45.00 ➝ $101.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$42.00 ➝ $70.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $101.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$71.00
7/23/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $95.00
7/18/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$33.00
7/18/2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform
(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$0.69 per shareN/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$650K231.38N/AN/A$3.53 per share1.28
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.20$0.21 per share21.66$2.09 per share2.18
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$1.75 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$190.71MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$98.33M-$3.30N/AN/AN/AN/A-85.86%-68.48%8/11/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-1.92%-0.36%-0.20%N/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)

Latest LXEO, VIGL, ORGO, and ABVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9220N/AN/AN/A$1.19 millionN/A
8/11/2025Q2 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.61N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
5/12/2025Q1 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.80-$0.99-$0.19-$0.99N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
1.29
1.25
1.25
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
0.01
3.42
3.42
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
2.97
2.97

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6163.47 millionN/ANot Optionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5833.20 million31.44 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4047.69 million39.10 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$70.13 +0.11 (+0.16%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$69.78 -0.35 (-0.50%)
As of 08/8/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$4.53 +0.08 (+1.80%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$4.53 0.00 (0.00%)
As of 08/8/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.55 +0.03 (+0.66%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$4.39 -0.16 (-3.41%)
As of 08/8/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)
As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.